


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound comprising of a formula:



or a pharmaceutically acceptable salt or a prodrug ~~or a metabolite thereof~~;

wherein Y is CO<sub>2</sub>(R<sup>2</sup>), CON(R<sup>2</sup>)<sub>2</sub>, CON(OR<sup>2</sup>)R<sup>2</sup>, CON(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>,


CONH(CH<sub>2</sub>CH<sub>2</sub>OH), CH<sub>2</sub>OH, P(O)(OH)<sub>2</sub>, CONHSO<sub>2</sub>R<sup>2</sup>, SO<sub>2</sub>N(R<sup>2</sup>)<sub>2</sub>, SO<sub>2</sub>NHR<sup>2</sup>, or  
tetrazolyl-R<sup>2</sup>; wherein each R<sup>2</sup> is independently H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, or biphenyl

~~an organic acid functional group, or an amide or ester thereof comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group;~~

A is -(CH<sub>2</sub>)<sub>6</sub>-, *cis* -CH<sub>2</sub>CH=CH-(CH<sub>2</sub>)<sub>3</sub>-, or -CH<sub>2</sub>C≡C-(CH<sub>2</sub>)<sub>3</sub>-, wherein 1 or 2 carbon atoms may be ~~substituted~~ replaced with S or O; or A is -(CH<sub>2</sub>)<sub>m</sub>-Ar-(CH<sub>2</sub>)<sub>o</sub>- wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one CH<sub>2</sub> may be ~~substituted~~ replaced with S or O; and D is aryl or heteroaryl.


2. (Original) The compound of claim 1 wherein D is phenyl.
3. (Original) The compound of claim 2 wherein D is chlorophenyl.
4. (Original) The compound of claim 3 wherein D is 3,5-dichlorophenyl.

5. (Original) The compound of claim 2 wherein D is unsubstituted phenyl.
6. (Original) The compound according to any one of claims 1 to 5, wherein A is  $-(CH_2)_6-$ , *cis*  $-CH_2CH=CH-$   $(CH_2)_3-$ , or  $-CH_2O\equiv C-(CH_2)_3-$ .
7. (Currently Amended) The compound of claim 2 ~~comprising~~ further represented by a formula:




or a pharmaceutically acceptable salt or a prodrug ~~or a metabolite~~ thereof;  
 wherein  $R^3$  is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy,  $NH_2$ , OH, CN,  $NO_2$ , or  $CF_3$ ; and  
 n is 0, 1, 2, or 3.

8. (Currently Amended) The compound of claim 7 ~~comprising~~ further represented by a formula:




or a pharmaceutically acceptable salt or a prodrug ~~or a metabolite~~ thereof;  
 wherein a dashed line indicates the presence or absence of a covalent bond.

9. (Currently Amended) The compound of claim 2 comprising



or a pharmaceutically acceptable salt or a prodrug ~~or a metabolite~~ thereof;  
 wherein  $R^3$  is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy,  $NH_2$ , OH, CN,  $NO_2$ , or  $CF_3$ ;  
 $R^4$  is hydroxyhydrocarbonyl having from 1 to 10 carbon atoms; and  
 $n$  is 0, 1, 2, or 3.


10. (Currently Amended) A method comprising administering an effective amount of a compound to a mammal for the treatment or prevention of glaucoma or ocular hypertension, said compound ~~comprising~~ represented by a formula:



or a pharmaceutically acceptable salt or a prodrug ~~or a metabolite~~ thereof;  
 wherein  $Y$  is  $CO_2(R^2)$ ,  $CON(R^2)_2$ ,  $CON(OR^2)R^2$ ,  $CON(CH_2CH_2OH)_2$ ,  $CONH(CH_2CH_2OH)$ ,  $CH_2OH$ ,  $P(O)(OH)_2$ ,  $CONHSO_2R^2$ ,  $SO_2N(R^2)_2$ ,  $SO_2NHR^2$ , or tetrazolyl- $R^2$ ; wherein each  $R^2$  is independently H,  $C_1$ - $C_6$  alkyl, phenyl, or biphenyl  
~~an organic acid functional group, or an amide or ester thereof comprising up to 12 carbon atoms; or  $Y$  is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or  $Y$  is a tetrazolyl functional group;~~  
 $A$  is  $-(CH_2)_6-$ ,  $cis$ - $CH_2CH=CH-(CH_2)_3-$ , or  $-CH_2C\equiv C-(CH_2)_3-$ , wherein 1 or 2 carbon atoms may be ~~substituted~~ replaced with S or O; or  $A$  is  $-(CH_2)_m$ -Ar- $(CH_2)_o-$  wherein Ar is

interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one CH<sub>2</sub> may be ~~substituted~~ replaced with S or O; and D is aryl or heteroaryl.

11. (Currently Amended) A liquid comprising a compound and a liquid carrier, wherein said liquid is ophthalmically acceptable, said compound ~~comprising~~ represented by a formula:



or a pharmaceutically acceptable salt or a prodrug ~~or a metabolite thereof~~;  
wherein Y is CO<sub>2</sub>(R<sup>2</sup>), CON(R<sup>2</sup>)<sub>2</sub>, CON(OR<sup>2</sup>)R<sup>2</sup>, CON(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, CONH(CH<sub>2</sub>CH<sub>2</sub>OH), CH<sub>2</sub>OH, P(O)(OH)<sub>2</sub>, CONHSO<sub>2</sub>R<sup>2</sup>, SO<sub>2</sub>N(R<sup>2</sup>)<sub>2</sub>, SO<sub>2</sub>NHR<sup>2</sup>, or tetrazolyl-R<sup>2</sup>; wherein each R<sup>2</sup> is independently H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, or biphenyl  
~~an organic acid functional group, or an amide or ester thereof comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group;~~  
A is -(CH<sub>2</sub>)<sub>6</sub>-, *cis* -CH<sub>2</sub>CH=CH-(CH<sub>2</sub>)<sub>3</sub>-, or -CH<sub>2</sub>C≡C-(CH<sub>2</sub>)<sub>3</sub>-, wherein 1 or 2 carbon atoms may be ~~substituted~~ replaced with S or O; or A is -(CH<sub>2</sub>)<sub>m</sub>-Ar-(CH<sub>2</sub>)<sub>o</sub>- wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one CH<sub>2</sub> may be ~~substituted~~ replaced with S or O; and D is aryl or heteroaryl.

12. (Cancelled)

13. (New) The method of claim 10, wherein D is phenyl.

14. (New) The method of claim 13 wherein D is 3,5-dichlorophenyl.

15. (New) The method of claim 13, wherein Ar is interphenylene, interthienylene, interfurylene, interoxazolylene, or interthiazolylene.
16. (New) The method of claim 15, wherein Ar is unsubstituted, or all substituents present on Ar are independently C<sub>1-4</sub> alkyl, CF<sub>3</sub>, F, Cl, Br, OH, and NH<sub>2</sub>.
17. (New) The liquid of claim 11, wherein Y is CO<sub>2</sub>(R<sup>2</sup>) or CON(R<sup>2</sup>)<sub>2</sub>.
18. (New) The liquid of claim 17, wherein D is phenyl.
19. (New) The liquid of claim 11, wherein Ar is interthienylene.
20. (New) The liquid of claim 19, wherein D is phenyl.
21. (New) The liquid of claim 20, wherein Ar is interthienylene and Y is CO<sub>2</sub>(R<sup>2</sup>).